

Datasheet: MCA1037PE

BATCH NUMBER 1802

Description:	RAT ANTI DOG CD5:RPE
Specificity:	CD5
Format:	RPE
Product Type:	Monoclonal Antibody
Clone:	YKIX322.3
Isotype:	IgG2a
Quantity:	100 TESTS/1ml

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
Flow Cytometry	▪			Neat

Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own systems with appropriate negative/positive controls.

Target Species	Dog		
Product Form	Purified IgG conjugated to R. Phycoerythrin (RPE) - lyophilized		
Reconstitution	Reconstitute with 1.0 ml distilled water		
Max Ex/Em	Fluorophore	Excitation Max (nm)	Emission Max (nm)
	RPE 488nm laser	496	578
Preparation	Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant		
Buffer Solution	Phosphate buffered saline		
Preservative	0.09% Sodium Azide		
Stabilisers	1%	Bovine Serum Albumin	
	5%	Sucrose	

Immunogen	Concanavilin A activated canine peripheral blood cells
RRID	AB_324035
Fusion Partners	Spleen cells from an immunised DA rat were fused with cells of the rat Y3/Ag1.2.3 myeloma cell line
Specificity	<p>Rat anti Dog CD5 antibody, clone YKIX322.3 recognizes canine CD5, a 67 kDa cell surface type 1 transmembrane glycoprotein also known as lymphocyte antigen T1, Ly-1 or Leu-1. CD5 is expressed on the surface of T-cells and thymocytes, CD5 is also expressed by NK cells at low levels (Huang <i>et al.</i> 2008). Rat anti dog CD5, clone YKIX322.3 was clustered as canine CD5 in the First Canine Leucocyte Antigen Workshop (Cobbold <i>et al.</i> 1994).</p> <p>In a study of 73 cases of canine chronic lymphocytic leukemia (CLL) CD5 expression was absent on all cases of B-cell CLL as defined by CD21 expression and lack of CD3 or other T cell antigen expression (Vernau and Moore 1999). Rat anti dog CD5 serves as a useful marker for the discrimination of canine leukemias of differing origins (Deravi <i>et al.</i> 2017).</p>
Flow Cytometry	Use 10ul of the suggested working dilution to label 10 ⁶ cells in 100ul.
References	<ol style="list-style-type: none"> 1. Cobbold, S/ & Metcalfe, S. (1994) Monoclonal antibodies that define canine homologues of human CD antigens: summary of the First International Canine Leukocyte Antigen Workshop (CLAW). Tissue Antigens. 43 (3): 137-54. 2. Hewicker-Trautwein, M. <i>et al.</i> (1999) Immunocytochemical demonstration of lymphocyte subsets and MHC class II antigen expression in synovial membranes from dogs with rheumatoid arthritis and degenerative joint disease. Vet Immunol Immunopathol. 67 (4): 341-57. 3. Huang, Y.C. (2008) CD5-low expression lymphocytes in canine peripheral blood show characteristics of natural killer cells. J Leukoc Biol. 84: 1501-10. 4. Araújo, M.S. <i>et al.</i> (2011) Immunological changes in canine peripheral blood leukocytes triggered by immunization with first or second generation vaccines against canine visceral leishmaniasis. Vet Immunol Immunopathol. 141: 64-75. 5. Burnett, R.C. <i>et al.</i> (2003) Diagnosis of canine lymphoid neoplasia using clonal rearrangements of antigen receptor genes. Vet Pathol. 40: 32-41. 6. Fosmire, S.P. <i>et al.</i> (2007) Inactivation of the p16 cyclin-dependent kinase inhibitor in high-grade canine non-Hodgkin's T-cell lymphoma. Vet Pathol. 44: 467-78. 7. Guarga, J.L. <i>et al.</i> (2002) Evaluation of a specific immunochemotherapy for the treatment of canine visceral leishmaniasis. Vet Immunol Immunopathol. 88: 13-20. 8. Vernau, W. Moore, P.F. <i>et al.</i> (1999) An immunophenotypic study of canine leukemias and preliminary assessment of clonality by polymerase chain reaction. Vet Immunol Immunopathol. 69: 145-64. 9. Lamerato-kozicki, A.R. <i>et al.</i> (2006) Canine hemangiosarcoma originates from hematopoietic precursors with potential for endothelial differentiation. Exp Hematol. 34 (7): 870-8. 10. Rütgen BC <i>et al.</i> (2012) Authentication of primordial characteristics of the CLBL-1 cell line prove the integrity of a canine B-cell lymphoma in a murine in vivo model. PLoS One.

[7 \(6\): e40078.](#)

11. Aresu, L. *et al.* (2014) VEGF and MMP-9: biomarkers for canine lymphoma. [Vet Comp Oncol. 12: 29-36.](#)
12. Moreira, M.L. *et al.* (2016) Vaccination against canine leishmaniosis increases the phagocytic activity, nitric oxide production and expression of cell activation/migration molecules in neutrophils and monocytes. [Vet Parasitol. 220: 33-45.](#)
13. Gelain, M.E. *et al.* (2014) CD44 in canine leukemia: analysis of mRNA and protein expression in peripheral blood. [Vet Immunol Immunopathol. 159 \(1-2\): 91-6.](#)
14. Michael, H.T. *et al.* (2013) Isolation and characterization of canine natural killer cells. [Vet Immunol Immunopathol. 155 \(3\): 211-7.](#)
15. Karayannopoulou, M. *et al.* (2017) Evaluation of blood T-lymphocyte subpopulations involved in host cellular immunity in dogs with mammary cancer. [Vet Immunol Immunopathol. 186: 45-50.](#)
16. Bonnefont-Rebeix, C. *et al.* (2016) Characterization of a novel canine T-cell line established from a spontaneously occurring aggressive T-cell lymphoma with large granular cell morphology. [Immunobiology. 221 \(1\): 12-22.](#)
17. Gibbons, N. *et al.* (2017) Phenotypic heterogeneity of peripheral monocytes in healthy dogs. [Vet Immunol Immunopathol. 190: 26-30.](#)
18. Deravi, N. *et al.* (2017) Specific immunotypes of canine T cell lymphoma are associated with different outcomes. [Vet Immunol Immunopathol. 191: 5-13.](#)
19. GomesMde, O. *et al.* (2011) Old beagle dogs have lower faecal concentrations of some fermentation products and lower peripheral lymphocyte counts than young adult beagles. [Br J Nutr. 106 Suppl 1: S187-90.](#)
20. MariaA, P.J. *et al.* (2017) The effect of age and carbohydrate and protein sources on digestibility, fecal microbiota, fermentation products, fecal IgA, and immunological blood parameters in dogs. [J Anim Sci. 95 \(6\): 2452-66.](#)
21. Stokol, T. *et al.* (2015) Alkaline phosphatase is a useful cytochemical marker for the diagnosis of acute myelomonocytic and monocytic leukemia in the dog. [Vet Clin Pathol. 44 \(1\): 79-93.](#)
22. Martini, V. *et al.* (2019) Prognostic role of non-neoplastic lymphocytes in lymph node aspirates from dogs with diffuse large B-cell lymphoma treated with chemo-immunotherapy. [Res Vet Sci. 125: 130-5.](#)
23. Lin, C.S. *et al.* (2018) Activating natural killer (NK) cytotoxicity of canine CD5⁺CD21⁺ cells requires low surface CD5 density NK cells. [Iran J Vet Res. 19 \(2\): 87-95.](#)
24. Roatt, B.M. *et al.* (2017) A Vaccine Therapy for Canine Visceral Leishmaniasis Promoted Significant Improvement of Clinical and Immune Status with Reduction in Parasite Burden. [Front Immunol. 8: 217.](#)
25. Aricò, A. *et al.* (2013) The role of vascular endothelial growth factor and matrix metalloproteinases in canine lymphoma: *in vivo* and *in vitro* study. [BMC Vet Res. 9: 94.](#)
26. Aguiar-Soares, R.D.O. *et al.* (2020) Phase I and II Clinical Trial Comparing the LBSap, Leishmune[®], and Leish-Tec[®] Vaccines against Canine Visceral Leishmaniasis. [Vaccines \(Basel\). 8 \(4\)Nov 17 \[Epub ahead of print\].](#)
27. Graves, S.S. *et al.* (2019) Development and characterization of a canine-specific anti-CD94 (KLRD-1) monoclonal antibody. [Vet Immunol Immunopathol. 211: 10-8.](#)
28. Ito, D. *et al.* (2015) A double blinded, placebo-controlled pilot study to examine reduction of CD34⁺/CD117⁺/CD133⁺ lymphoma progenitor cells and duration of remission induced by neoadjuvant valspodar in dogs with large B-cell lymphoma.

[F1000Res. 4: 42.](#)

29. Wolf-Ringwall, A. *et al.* (2020) Prospective evaluation of flow cytometric characteristics, histopathologic diagnosis and clinical outcome in dogs with naïve B-cell lymphoma treated with a 19-week CHOP protocol. [Vet Comp Oncol. 18 \(3\): 342-52.](#)
30. Sayag, D. *et al.* (2020) Proof-of-concept study: Evaluation of plasma and urinary electrolytes as markers of response to L-asparaginase therapy in dogs with high-grade lymphoma. [Vet Clin Pathol. 49 \(3\): 476-83.](#)
31. Lee, J. *et al.* (2021) Canine Natural Killer Cell-Derived Exosomes Exhibit Antitumor Activity in a Mouse Model of Canine Mammary Tumor. [Biomed Res Int. 2021: 6690704.](#)
32. Grudzien, M. *et al.* (2021) A newly established canine NK-type cell line and its cytotoxic properties. [Vet Comp Oncol. 19 \(3\): 567-77.](#)
33. Lee, S.H. *et al.* (2021) Safety and immunological effects of recombinant canine IL-15 in dogs. [Cytokine. 148: 155599.](#)
34. Karayannopoulou, M. *et al.* (2022) Effect of major versus minor mastectomy on host immunity in canine mammary cancer [Vet Immunol Immunopathol. 24 Feb: 110403.](#)
35. Riccardo, F. *et al.* (2022) Antigen mimicry as an effective strategy to induce CSPG4-targeted immunity in dogs with oral melanoma: a veterinary trial. [J Immunother Cancer. 10 \(5\): e004007. \[Epub ahead of print\].](#)
36. Jaensch, S. *et al.* (2022) Clinicopathologic and immunophenotypic features in dogs with presumptive large granular lymphocyte leukaemia [Australian Veterinary Journal. \[Epub ahead of print\].](#)

Storage

Prior to reconstitution store at +4°C. Following reconstitution store at +4°C.

DO NOT FREEZE.

This product should be stored undiluted. This product is photosensitive and should be protected from light. Should this product contain a precipitate we recommend microcentrifugation before use.

Guarantee

12 months from date of despatch

Health And Safety Information

Material Safety Datasheet documentation #20487 available at: <https://www.bio-rad-antibodies.com/SDS/MCA1037PE>
20487

Regulatory

For research purposes only

Related Products

Recommended Negative Controls

[RAT IgG2a NEGATIVE CONTROL:RPE \(MCA1212PE\)](#)

[RAT IgG2a NEGATIVE CONTROL:RPE \(MCA6005PE\)](#)

North & South America

Tel: +1 800 265 7376

Fax: +1 919 878 3751

Email: antibody_sales_us@bio-rad.com

Worldwide

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: antibody_sales_uk@bio-rad.com

Europe

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: antibody_sales_de@bio-rad.com

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](https://www.bio-rad-antibodies.com/datasheets)

Printed on 05 Mar 2024